With over 40 years' experience, Rentschler is one of the industry leaders for contract development and manufacturing (CDMO) focused on mammalian cell lines. Delivering successful projects allows us to make an essential contribution to the global availability of biotechnological pharmaceuticals. Rentschler is an independent, privately-held company and set new standards in client focus, individual customised solutions and reliability.
From gene to vial - focused on mammalian cell lines, our experience covers the development and manufacturing of recombinant proteins such as monoclonal antibodies, fusion proteins, cytokines and enzymes in compliance with international GMP standards (EMA/FDA). GMP certified suites with stainless steel bioreactors up to 3,000L and single-use bioreactors with volumes of up to 2,000L, support the flexible and customised cost-efficient manufacturing of material demanded by our global clients. In addition, Rentschler's fill and finish facility offers aseptic liquid filling in vials, lyophilisates and aseptic liquid filling of prefilled syringes. Our many successful projects and long-term client relationships directly illustrate our experience and reliability.
Rentschler is one of the first CDMO manufacturers worldwide to establish a complete single-use facility for the upstream and downstream processes. The implementation of a flexible disposable concept consisting of two multi-product, single-use bioreactor systems with 2 x 1,000L volume of work and an additional 2,000L bioreactor allow us an easy scale-up as well as reduce manufacturing costs and product cycle times. The significant reduction of time-consuming cleaning and sterilisation as well as very rapid product changes allow our customers the quickest possible time to market.
Our success as a CDMO is underpinned by our focus on product quality, on-time delivery as well as comprehensive and tailored project management. This is further supported by the profound knowledge and scientific strength of our team.
Rentschler employs cutting-edge technologies to ensure safe and stable cell culture and protein purification processes. Our state-of-the-art facilities and processes including batch, fed-batch, continuous and perfusion processing allow us to manufacture material for clinical phases and commercial supplies. Rentschler's proprietary TurboCell™ mammalian expression platform enables the simultaneous production of up to 20 early-stage drug candidate variants and fast supply of material to be used in early drug testing and pre-clinical studies.
Our experience with international regulatory affairs allows us to maximise approval rates, which can reduce not only the time-to-market but also support the overall success of the client's project. The Rentschler brand stands for expert guidance, long-term experience, flexibility and innovation, all of which help deliver the right solutions for our clients.